Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer

Oncology

Volumn 70, Issue 3, 2006, Pages 238-244

  Gloeckner Hofmann, Katharina ^a   Guillén Gómez, Elena ^b   Schmidtgen, Claudia ^a   Porstmann, Romy ^a   Ziegler, Ralf ^a   Stoss, Oliver ^a   Casado, F Javier ^b   Rüschoff, Josef ^a   Pastor Anglada, Marçal ^b  

^a KLINIKUM KASSEL   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Breast cancer; Fluoropyrimidine based chemotherapy; Nucleoside transporters

Indexed keywords

BIOLOGICAL MARKER; CELL MEMBRANE PROTEIN; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; METHOTREXATE; NUCLEIC ACID BASE; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRANSPORTER; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DRUG METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METABOLISM; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746656174     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094541     Document Type: Article

References (34)

1. Cassidy J: Potential of Xeloda in colorectal cancer and other solid tumors. Oncology 1999;57(suppl 1):27-32.
2. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK: Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999;17:1915-1925.
3. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
4. Moertel CG, Gunderson LL, Mailliard, JA, McKenna PJ, Martenson JA Jr, Burch PA, Cha SS: Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol 1994;12:21-27.
5. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18:1337-1345.
6. Furuya Y, Yamamoto K, Kohno N, Kuh Y, Saitoh Y: 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitivehuman breast cancer cells (MCF7). Cancer Lett 1994;81:95-98.
7. Verweij J: Rational design of new tumor-activated cytotoxic agents. Oncology 1999;57(suppl 1):9-15.
8. Ackland SP, Peters GJ: Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 1999;2:205-214.
9. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL: Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 1997;8:271-275.
10. Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999;5:101-111.
11. Yang Q, Barbareschi M, Mori I, Mauri F, Muscara M, Nakamura M, Nakamura Y, Yoshimura G, Sakurai T, Caffo O, Galliogioni E, Dalla Palma P, Kakudo K: Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 2002;97:512-517.
12. Horiguchi J, Yoshida T, Koibuchi Y, Iijima K, Ninomiya J, Takei H, Yokoe T, lino Y, Morishita Y: DPD activity and immunohistochemical DPD expression in human breast cancer. Oncol Rep 2004;11:65-72.
13. Li H, Suo Z, Zhang Y, Risberg B, Karlsson MG, Villman K, Nesland JM: The prognostic significance of thymidine phosphorylase, thymidylate synthase and didhydropyrimidine dehydrogenase mRNA expression in breast carcinomas. Histol Histopathol 2004;19:129-136.
14. Damaraju V L, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE: Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003;22:7524-7536.
15. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM: Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004;65:512-519.
16. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J: Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004;18:385-393.
17. Pastor-Anglada M, Casado FJ, Valdes R, Mata J, Garcia-Manteiga J, Molina M: Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol Membr Biol 2001;18:81-85.
18. Valdes R, Casado FJ, Pastor-Anglada M: Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun 2002;296:575-579.
19. Duflot S, Calvo M, Casado FJ, Enrich C, Pastor-Anglada M: Concentrative nucleoside transporter (rCNT1) is targeted to the apical membrane through the hepatic transcytotic pathway. Exp Cell Res 2002;281:77-85.
20. Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ, Pastor-Anglada M: Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5′-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 2001;59:1542-1548.
21. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-4357.
22. Garcia-Manteiga JM, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003;9:5000-5008.
23. del Santo B, Valdes R, Mata J, Felipe A, Casado FJ, Pastor-Anglada M: Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. Hepatology 1998;28:1504-1511.
24. del Santo B, Tarafa G, Felipe A, Casado FJ, Pastor-Anglada M: Developmental regulation of the concentrative nucleoside transporters CNT1 and CNT2 in rat liver. J Hepatol 2001;34:873-880.
25. Dragan Y, Valdes R, Gomez-Angelats M, Felipe A, Javier Casado F, Pilot H, Pastor-Anglada M: Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 2000;32:239-246.
26. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M: Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004;112:959-966.
27. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956-6961.
28. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR: Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 2001;280:951-959.
29. Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, Hanson J, Young JD, Merle-Beral H, Binet JL, Cass CE, Dumontet C: Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and insensitive populations. Blood 2004;105:767-774.
30. Clark GM, McGuire WL: New biologic prognostic factors in breast cancer. Oncology (Huntingt) 1989;3:49-54; discussion 58, 61, 64.
31. Kinsella AR, Smith D, Pickard M: Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997;75:935-945.
32. Cole PD, Smith AK, Kamen BA: Ostosarcoma cells, resitant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol 2002;50:111-116.
33. Weber G, Nagai M, Natsumeda Y, Ichikawa S, Nakamura H, Eble JN, Jayaram HN, Zhen WN, Paulik E, Hoffman R, Tricot G: Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul 1991;31:45-67.
34. Zhen YS, Taniki T, Weber G: Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncol Res 1992;4:73-78.